Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

被引：0
|
作者：
Edoardo Caronna
Victor José Gallardo
Alicia Alpuente
Marta Torres-Ferrus
Patricia Pozo-Rosich
机构：
[1] Universitat Autònoma de Barcelona,Neurology Department, Hospital Universitari Vall d’Hebron, Department of Medicine
[2] Universitat Autònoma de Barcelona,Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Medicine
来源：
The Journal of Headache and Pain | 2021年 / 22卷
关键词：
Migraine; Medication overuse; CGRP; Monoclonal antibodies; Erenumab; Galcanezumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Impact of migraine attack accompanying symptoms in treatment response to anti-CGRP monoclonal antibodies treatment and their evolution after 6 months
    Alpuente, A.
    Torre-Sune, A.
    Caronna, E.
    Torres-Ferrus, M.
    Pozo-Rosich, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [22] Real-world evidence for frequency of constipation with the use of anti-CGRP monoclonal antibodies in chronic migraine
    Uzun, S.
    Frejvall, U.
    Sahin, G. Ozkaya
    Sahin, G.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [23] Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
    Sevivas, Hugo
    Fresco, Paula
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [24] Could Symptom Severity Predict the Response to Anti-Cgrp Monoclonal Antibodies in Migraine?
    Membrilla, J. A.
    Ruiz Castrillo, M. J.
    Sastre Real, M.
    Sanchez Casado, L.
    Marino Trillo, E.
    Corral, C.
    Estebas, C.
    Gonzalez Sarmiento, R.
    Lorenzo, M.
    Diaz de Teran, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [25] Could symptom severity predict the response to anti-CGRP monoclonal antibodies in migraine?
    Membrilla, J.
    Ruiz Castrillo, M.
    Sastre Real, M.
    Sanchez Casado, L.
    Trillo Marino, E.
    Corral, C.
    Estebas, C.
    Gonzalez Sarmiento, R.
    Lorenzo, M.
    Diaz de Teran, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 413 - 413
  • [26] Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
    Caronna, Edoardo
    Gallardo, Victor Jose
    Egeo, Gabriella
    Vazquez, Manuel Millan
    Castellanos, Candela Nieves
    Membrilla, Javier A.
    Vaghi, Gloria
    Rodriguez-Montolio, Joana
    Fabra, Neus Fabregat
    Sanchez-Caballero, Francisco
    Sanchez, Alex Jaimes
    Munoz-Vendrell, Albert
    Oliveira, Renato
    Garate, Gabriel
    Gonzalez-Osorio, Yesica
    Guisado-Alonso, Daniel
    Ornello, Raffaele
    Thunstedt, Cem
    Fernandez-Lazaro, Iris
    Torres-Ferrus, Marta
    Alpuente, Alicia
    Torelli, Paola
    Aurilia, Cinzia
    Pere, Raquel Lamas
    Castrillo, Maria Jose Ruiz
    De Icco, Roberto
    Sances, Grazia
    Broadhurst, Sarah
    Ong, Hui Ching
    Garcia, Andrea Gomez
    Campoy, Sergio
    Sanahuja, Jordi
    Cabral, Goncalo
    Blasco, Isabel Beltran
    Waliszewska-Prosol, Marta
    Pereira, Liliana
    Layos-Romero, Almudena
    Luzeiro, Isabel
    Dorado, Laura
    Escudero, Maria Rocio Alvarez
    May, Arne
    Lopez-Bravo, Alba
    Martins, Isabel Pavao
    Sundal, Christina
    Irimia, Pablo
    Ros, Alberto Lozano
    Gago-Veiga, Ana Beatriz
    Juanes, Fernando Velasco
    Ruscheweyh, Ruth
    Sacco, Simona
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (10): : 927 - 937
  • [27] Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Migraine
    Hennessy, Elise
    Salim, Amira
    Biswas, Sudipa
    Suneja, Aarushi
    Mays, Maryann
    Ahmed, Zubair
    Mata, Ignacio
    NEUROLOGY, 2023, 100 (17)
  • [28] Work impact and cost-effectiveness of anti-CGRP monoclonal antibodies in patients with migraine
    Lazaro, C.
    Caronna, E.
    Alpuente, A.
    De la Torre, A.
    Torres, M.
    Pozo-Roisch, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 487 - 488
  • [29] Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
    Munoz-Vendrell, Albert
    Campoy, Sergio
    Caronna, Edoardo
    Alpuente, Alicia
    Torres-Ferrus, Marta
    Nieves Castellanos, Candela
    Olivier, Marina
    Campdelacreu, Jaume
    Prat, Joan
    Camina Muniz, Javier
    Molina Martinez, Francisco Jose
    Minguez-Olaondo, Ane
    Ruibal Salgado, Marta
    Santos Lasaosa, Sonia
    Navarro Perez, Maria Pilar
    Morollon, Noemi
    Lopez Bravo, Alba
    Cano Sanchez, Luis Miguel
    Garcia-Sanchez, Sonia Maria
    Garcia-Ull, Jesica
    Rubio-Flores, Laura
    Gonzalez-Martinez, Alicia
    Quintas, Sonia
    Echavarria Iniguez, Ana
    Gil Luque, Sendoa
    Castro-Sanchez, Maria Victoria
    Adell Ortega, Vanesa
    Garcia Alhama, Jessica
    Berrocal-Izquierdo, Nuria
    Belvis, Robert
    Diaz-Insa, Samuel
    Pozo-Rosich, Patricia
    Huerta-Villanueva, Mariano
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [30] Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
    Amy R. Tso
    Peter J. Goadsby
    Current Treatment Options in Neurology, 2017, 19
12345